Amgen (AMGN) closed at $273.68 in the latest trading session, marking a -1.3% move from the prior day. This change was narrower than the S&P 500's 2.36% loss on the day. Meanwhile, the Dow lost 2. ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the United States. And unless a court rules otherwise, the Southern ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Learn how a 25% Pharma tariff could raise U.S. drug costs by nearly $51 billion annually and impact prices significantly.

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth out of another drug from its $27.8 billion Horizon Therapeutics buy.

As you can see from the chart above the percentage of shares that are sold short for Amgen has declined since its last report. This does not mean that the stock is going to rise in the near-term ...

Amgen, known for its focus on human therapeutics, has maintained a strong presence in the biotech industry. The company's product portfolio spans various therapeutic areas, including oncology ...